IONIS PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Trading Plans
During the quarter ended December 31, 2024, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act), or Section 16 officers and directors, adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted in the table below.
| * | Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. |
|---|
| ** | “Non-Rule 10b5-1 trading arrangement” as defined in item 408(c) of Regulation S-K under the Exchange Act. |
|---|
| Action | Date | Trading Arrangement | Total Shares to be Sold | Expiration Date | |
|---|---|---|---|---|---|
| Rule 10b5-1* | Non-Rule 10b5-1** | ||||
| Joseph Wender, Board Member | Adoption | December 26, 2024 | X | 104,079 | February 28, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.